As of 8 Nov 2026, Cheiron has raised $8M across 1 verified round on record; latest: $8M seed round led by Menlo Ventures, announced 22 Jul 2026.
Cheiron sells a platform that connects and manages all aspects of drug development programs.
cheiron.bioLinkedInLos Altos, CaliforniaHealthtechFounded 2024
7 sources
The company release states an $8 million seed round led by Menlo Ventures and dates the announcement July 22, 2026. Sources 1 and 2 are dated or display July 23, but the company's GlobeNewswire release and dateline fix the announcement day as July 22; Source 2 additionally says Josh Meier, Laxman Narasimhan, and John Giannandrea took part in the round, while Robert Langer and Freda Lewis-Hall are described as strategic advisors rather than investors.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $8M | 2026-07-22 | Menlo Ventures | No recent discussion |
7 sources [ VERIFIED ] read against 7 sources The company release states an $8 million seed round led by Menlo Ventures and dates the announcement July 22, 2026. Sources 1 and 2 are dated or display July 23, but the company's GlobeNewswire release and dateline fix the announcement day as July 22; Source 2 additionally says Josh Meier, Laxman Narasimhan, and John Giannandrea took part in the round, while Robert Langer and Freda Lewis-Hall are described as strategic advisors rather than investors. | ||||
Cheiron builds an AI-native operating system and workbench that helps biopharma teams connect, query, verify, and manage the evidence, decisions, risks, and commitments across drug-development programs.
Drug-development knowledge is scattered across papers, trials, filings, patents, datasets, and institutional memory, so teams spend substantial time reconstructing context before making decisions. Cheiron is betting that its Life Sciences Knowledge Graph can turn a drug program into a connected, auditable system; its latest disclosed traction was seven of Korea's top 10 biopharma companies as customers, while the $8 million seed is intended to expand the graph and clinical, regulatory, and strategic workflows.
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Seed | $4 million | 2025-08-04 | SK Networks | |
Checked against 10 sources on Sep 23
Also named as backers in company research: SK Networks, Aidan Gomez, Illia Polosukhin, Robert Langer, Freda Lewis-Hall